PBAC to advise on GLP-1s for obesity

Nicholas O’Donoghue 15/12/2025

Medicines advisory body notes “unmet clinical need for obesity treatments”, following deliberations on equitable access to GLP-1s The Pharmaceutical Benefits Advisory Committee (PBAC) will respond to the Minister for Health, Disability and Ageing’s request for advice on equitable access to glucagon-like peptide-1 (GLP-1) medications in the coming weeks. In an update following its November 2025 meeting, the PBAC noted that it had “finalised its

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

PBAC to advise on GLP-1s for obesity

Previous Sexual misconduct findings to remain on rego

Next ‘Have you ever wondered what it can feel like to have ADHD?’

MENU

ajp.com.au

Previous Sexual misconduct findings to remain on rego

Next ‘Have you ever wondered what it can feel like to have ADHD?’

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.